Physicians' Academy for Cardiovascular Education

A minority of FH patients is identified and labeled as such, which impacts treatment

Aug. 29, 2016 - ESC Rome, Italy - Prof. Kausik Ray, MD (London, UK)
##SCROLLER_ITEMS_FULL_TITLE##

Impacting lipid disorders through personalised healthcare

Feb. 2, 2016 - VBWG, Orlando - Daniel J. Rader, M.D.
##SCROLLER_ITEMS_FULL_TITLE##

Lipid Management 2020: A glance at the future

Sep. 24, 2015
##SCROLLER_ITEMS_FULL_TITLE##

Homozygous FH: treatment challenges

May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Frederick Raal
##SCROLLER_ITEMS_FULL_TITLE##

TAUSSIG: clinically relevant LDL-lowering in difficult to treat patients

June 15, 2015 - ISA2015, Amsterdam - Prof. Frederick Raal
##SCROLLER_ITEMS_FULL_TITLE##

Screening for Familial Hypercholesterolaemia

May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - dr. Kees Hovingh
##SCROLLER_ITEMS_FULL_TITLE##

Unique Dutch collaborative effort to identify FH patients

Apr. 1, 2015 - Amersfoort, The Netherlands - Dr. Janneke Wittekoek
##SCROLLER_ITEMS_FULL_TITLE##

2014: the major lipid developments in review

Dec. 20, 2014 - Amsterdam - Prof. John JP Kastelein
##SCROLLER_ITEMS_FULL_TITLE##

FH in Europe: Need for a registry

Nov. 10, 2014 - Zeist, The Netherlands - dr Kees Hovingh & Eric Bruckert
##SCROLLER_ITEMS_FULL_TITLE##

First European experience with human MTP-inhibitor in HoFH

Oct. 24, 2014
##SCROLLER_ITEMS_FULL_TITLE##

HoFH: New insights in prevalence and therapy

Oct. 26, 2014 - Snapshot 2014 - dr Kees Hovingh
##SCROLLER_ITEMS_FULL_TITLE##

HoFH: New insights and expanding therapeutic options

Sep. 6, 2014 - Snapshot 2014 - Dr. Kees Hovingh, AMC, Amsterdam, The Netherlands
##SCROLLER_ITEMS_FULL_TITLE##

Biology and validation of PCSK9 as a novel target to lower LDL-C

Aug. 30, 2014 - Barcelona, ESC - Prof. John JP Kastelein
##SCROLLER_ITEMS_FULL_TITLE##

Emerging therapies to lower LDL-cholesterol

May 8, 2014

Anti-inflammatory changes in response to PCSK9 antibody treatment in monocytes of FH patients

Feb. 20, 2017 - Bernelot Moens SJ et al., - Eur Heart J 2017

Circulating monocytes of FH patients not on statins showed a pro-inflammatory phenotype and intracellular lipid accumulation, which was reversed upon treatment with PCSK9 antibodies.

PCSK9 inhibitor significantly reduced CV risk in ASCVD patients in FOURIER outcomes study

Feb. 3, 2017 - news
Evolocumab FOURIER CV outcomes study lowers CV risk in high-risk patients. Simultaneously, a trial showed that the antibody against PCSK9 is non-inferior to placebo for the effect on cognitive function.

Evolocumab CV outcomes study meets primary and key secondary endpoints, showing reduced risk of CV events in those with ASCVD already on optimised statin therapy.

A minority of FH patients is identified and labeled as such, which impacts treatment

Aug. 29, 2016 - ESC Rome, Italy - Prof. Kausik Ray, MD (London, UK)
A minority of FH patients is identified and labeled as such, which impacts treatment

CSI Rome Kausik Ray was involved in a project which investigated in UK databases which proportion of the predicted population with FH has been identified and is labelled as such. Johanneke van den Berg and Corien Flint discuss the consequences of underdetection with him, and how this may be improved.

Animal study first step towards long-term gene therapy for homozygous FH

May 30, 2016 - news

EAS 2016 Gene therapy targeted at LDLR and HMGCR decreased LDL-c level and slowed atherosclerosis in mice.

Impacting lipid disorders through personalised healthcare

Feb. 2, 2016 - VBWG, Orlando - Daniel J. Rader, M.D.
##OVERVIEW_ITEMS_KEY_PHRASE##

Daniel Rader (Philadelphia, PA, USA) looks forward to a future of personalised medicine in FH, which should benefit from specific biomarkers and novel medications, to better treat this common lipid disorder. But first, FH patients need to be better identified.

Another PCSK9-antibody approved by FDA for treatment hypercholesterolaemia

Aug. 30, 2015 - news

Evolocumab is the second PCSK9 inhibitor that is approved for use in addition to diet and maximally-tolerated statin therapy in adult patients with heterozygous or homozygous familial hypercholesterolemia (HoFH), or clinical atherosclerotic cardiovascular disease.

Homozygous FH: treatment challenges

May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Frederick Raal
##OVERVIEW_ITEMS_KEY_PHRASE##

Lipid MC 2015 Prof. Frederick Raal considers the challenges to adequately lower LDL-c levels in patients with HoFH, and how they may be overcome in the near future.

TAUSSIG: clinically relevant LDL-lowering in difficult to treat patients

June 15, 2015 - ISA2015, Amsterdam - Prof. Frederick Raal
##OVERVIEW_ITEMS_KEY_PHRASE##

ISA2015 | Clinical Breakthroughs Based on the TAUSSIG study, a longer term study of treatment with PCSK9 inhibitor evolocumab in a relatively large group of patients with homozygous FH, prof. Frederick Raal concludes that we now have an additional therapy for these difficult to treat patients.

Screening for Familial Hypercholesterolaemia

May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - dr. Kees Hovingh
##OVERVIEW_ITEMS_KEY_PHRASE##

Lipid MC 2015 Dr. Kees Hovingh discusses recent insights into the actual prevalence of homozygous and heterozygous FH, how FH patients can best be identified, and how they should be managed.

European Atherosclerosis Society Consensus Panel Position Paper on Paediatric Familial Hypercholesterolaemia

May 25, 2015 - news

ISA 2015 The European Atherosclerosis Society (EAS) Consensus Panel publishes a position paper today that makes the case for renewed efforts to detect and manage FH children so as to reduce the burden of death and disability associated with this common condition.

Lipid Master Class

Amsterdam, May 22 - 23

Apr. 2, 2015 - news
##OVERVIEW_ITEMS_KEY_PHRASE##

We are pleased to announce our first PACE Lipid Master Class: 'A case-based approach to advanced lipid management' to be held on May 22-23, 2015 in Amsterdam, prior to ISA2015. The meeting will be held in collaboration with MedPace 'FH-Clinician'.

Unique Dutch collaborative effort to identify FH patients

Apr. 1, 2015 - Amersfoort, The Netherlands - Dr. Janneke Wittekoek
##OVERVIEW_ITEMS_KEY_PHRASE##

Dr. Janneke Wittekoek (director LEEFH Foundation) explains how a unique collaborative effort, paid for by reimbursements from insurance companies, sets out to find all patients with familial hypercholesterolaemia in The Netherlands.